Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients Currently Treated With ACEI and/or ARB Therapy
Conditions
Interventions
CTP-499
Placebo
Locations
49
United States
Agave Clinical Research
Tempe, Arizona, United States
Harrisburg Family Medical Center
Harrisburg, Arkansas, United States
Arkansas Primary Care Clinic
Little Rock, Arkansas, United States
Providence Clinical Research
Burbank, California, United States
California Institute of Renal Research
Chula Vista, California, United States
SC Clinical Research
Garden Grove, California, United States
Start Date
January 1, 2012
Primary Completion Date
January 1, 2015
Completion Date
January 1, 2015
Last Updated
August 16, 2021
NCT07547098
NCT06278207
NCT07493642
NCT07051005
NCT07241390
NCT06926660
Lead Sponsor
Concert Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions